PHE study shows vaccine efficacy against B.1.617.2 variant after two doses  

PHE study shows vaccine efficacy against B.1.617.2 variant after two doses

A new study by Public Health England (PHE) has shown that two doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.

The study found that, for the period from 5 April to 16 May:

  • The Pfizer/BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 (Kent) variant.
  • Two doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617.2 variant compared to 66% effectiveness against the B.1.1.7 variant.
  • Both vaccines were 33% effective against symptomatic disease from B.1.617.2, 3 weeks after the first dose compared to around 50% effectiveness against the B.1.1.7 variant.

The analysis included data for all age groups from 5 April to cover the period since the B.1.617.2 variant emerged. It included 1,054 people confirmed as having the B.1.617.2 variant through genomic sequencing, including participants of several ethnicities. Data published on Thursday 20 May for vaccine effectiveness covered the period since December for those aged over 65.

According to PHE, the difference in effectiveness between the vaccines after two doses may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer-BioNTech vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.

As with other variants, even higher levels of effectiveness are expected against hospitalisation and death. There are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B.1.617.2 variant. PHE will continue to evaluate this over the coming weeks.

Health and Social Care Secretary Matt Hancock said: “This new evidence is ground-breaking – and proves just how valuable our COVID-19 vaccination programme is in protecting the people we love.

“We can now be confident that over 20 million people – more than 1 in 3 – have significant protection against this new variant, and that number is growing by the hundreds of thousands every single day as more and more people get that vital second dose. I want to thank the scientists and clinicians who have been working around the clock to produce this research.

“It’s clear how important the second dose is to secure the strongest possible protection against COVID-19 and its variants – and I urge everyone to book in their jab when offered.”